Lotus Pharmaceuticals, Inc. Reports Strong 2008 Financi...(o increase between 30% and 40%from 2008 ...),Health

    Highlights of Recent Developments
    -- Management has decided to start the construction of Inner Mongolia
       plant buildings on May 9, 2009 and to attempt to complete it by the end
       of 2009.
    -- In addition to the cost of land use rights and related expenses
       (approximately $32.6 million) which Liang Fang has paid, other
       components of the project are yet to be funded, including construction
       costs of approximately $17.5 million, costs associated with the various
       production lines estimated at approximately $33.6 million and working
       capital of approximately $7.3 million.
    -- The Company entered into an intellectual rights transfer contract with
       Beijing Yipuan Bio-Medical Technology Co., Ltd. in December 2008 to
       acquire the drug Yipubishan, a highly effective and stable octreotide
       acetate injection solution, In the first quarter of 2009, the Company
       has paid up $7.9 million as required in the transfer. The Company
       believes this could contribute $11.0 million to 2009's sale revenues
       with net margin of 75%.
    -- The Company announced two drugs entering into clinical testing of SFDA
       in 2008, Isosorbide Mononitrate sustained release tablet, a highly
       effective drug for the prevention and treatment of angina; and
       Laevo-Bambutero a Class 1 drug to treat asthma.
    -- Lotus obtained the patent, along with exclusive production rights for
       Laevo-Bambutero in China, through the technology transfer agreement
       with Dongguan Kaifa for a cash payment of $7.0 million and a 3% royalty
       on products sales. The Company has already paid $2.9 million to
       Dongguan Kaifa. The Company intends to market Laevo-Bambutero as a
       better alternative to Bambutero for the treatment of asthma, since it
       uses an integra
'/>"/>
SOURCE  Lotus Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 
Related medicine news :

1. iEnterprises Launches iComply, Lotus Notes Email Archiving and Compliance Software
2. Lotus Pharmaceuticals, Inc. Purchases Intellectual Property Rights to an Established Prescription Drug
3. Lotus Pharmaceuticals, Inc. Purchases Land Use Rights to Grow its Business and Reduce Costs
4. Lotus Pharmaceuticals to Present at Rodman & Renshaw Conference
5. Lotus Pharmaceuticals Announces Conference Call to Discuss Second Quarter 2008 Results
6. Lotus Pharmaceuticals, Inc. Reaffirms its Confidence in Meeting its Make Good Target for Fiscal Year 2008
7. Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss First Quarter 2008 Results
8. Lotus Pharmaceuticals, Inc. Announces Resignation of Director Mel Rothberg
9. Lotus Pharmaceuticals, Inc. Announces Fourth Quarter and Fiscal Year 2007 Results
10. Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2007 Results
11. Lotus Pharmaceuticals Raises $5 Million in Private Placement